IMMG.US Immage Biotherapeutics Corp

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Oct 6, 2026
0.0001 0.0001
Market cap
USD 15.2K
P/E
-
P/B
0.68x
ROE
-15,351.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Feb 2017.

Is IMMG.US undervalued?

Graham number

The Graham number of Immage Biotherapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immage Biotherapeutics Corp fundamental analysis

No fundamental analysis for Immage Biotherapeutics Corp yet.

Immage Biotherapeutics Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immage Biotherapeutics Corp

Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015. The company was founded in 2012 and is headquartered in Bethesda, Maryland. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited.

Full company profile